LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

Начало・Списък с акции・Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

19.54 -1.06

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

19.47

Максимум

19.7

Ключови измерители
By Trading Economics
Приходи	25M -43M
Продажби	-3.6M 65M
EPS	-0.48
Марж на печалбата	-65.788
Служители	298
EBITDA	-16M -31M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+106.74% upside

Дивиденти
By Dow Jones
Следващи печалби	3.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-77M 1.8B
Предишно отваряне	20.6
Предишно затваряне	19.54

Настроения в новините

By Acuity

50%

161 / 344 Класиране в Healthcare

Syndax Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

29.05.2026 г., 23:08 ч. UTC

Придобивния, сливания и поглъщания

Family Offices Bypass Private Equity and Go Direct -- Barrons.com

29.05.2026 г., 23:06 ч. UTC

Придобивния, сливания и поглъщания

After a Series of Sales, Hims Director Buys Company Shares -- Barrons.com

29.05.2026 г., 20:53 ч. UTC

Печалби

Oil Declines Lift Stocks to Fresh Records -- WSJ

29.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

29.05.2026 г., 20:33 ч. UTC

Пазарно говорене

Canada Meets Only One of Three Criteria To Declare Recession -- Market Talk

29.05.2026 г., 20:11 ч. UTC

Печалби

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

29.05.2026 г., 19:47 ч. UTC

Печалби

These Were the Best and Worst S&P 500 Stocks in May -- Barrons.com

29.05.2026 г., 19:36 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures End Month With Gains -- Market Talk

29.05.2026 г., 19:34 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

29.05.2026 г., 19:34 ч. UTC

Пазарно говорене

Over Half of Canadian Industries Growing, Undermining Recession Talk -- Market Talk

29.05.2026 г., 19:22 ч. UTC

Пазарно говорене

Oil Falls as U.S., Iran Expected to Reach Agreement -- Market Talk

29.05.2026 г., 19:05 ч. UTC

Придобивния, сливания и поглъщания

Universal Music Group Rejects $65 Billion Takeover Bid From Bill Ackman's Pershing Square -- Barrons.com

29.05.2026 г., 18:19 ч. UTC

Пазарно говорене

Canada Technical Recession Chatter Rife But Per-Capita GDP Was Up -- Market Talk

29.05.2026 г., 18:12 ч. UTC

Придобивния, сливания и поглъщания

Universal Music Group Rejects $65 Billion Buyout Offer From Bill Ackman -- WSJ

29.05.2026 г., 18:11 ч. UTC

Пазарно говорене

Canada Households Reaching Limit at Keeping Spending in Positive Territory -- Market Talk

29.05.2026 г., 18:10 ч. UTC

Пазарно говорене

As BTC Long-Term Holders Rise, Short-Term Holders Flee -- Market Talk

29.05.2026 г., 17:55 ч. UTC

Печалби

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

29.05.2026 г., 17:55 ч. UTC

Пазарно говорене

NEAR Protocol Nearly Doubles in May -- Market Talk

29.05.2026 г., 17:38 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Rises for Fifth Straight Week -- Market Talk

29.05.2026 г., 17:00 ч. UTC

Печалби

Okta Stock Soars After Earnings. Results Aren't the Real Catalyst. -- Barrons.com

29.05.2026 г., 16:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

29.05.2026 г., 16:20 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

29.05.2026 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

29.05.2026 г., 16:02 ч. UTC

Пазарно говорене

Gold Extend Gains as Investors Await U.S.-Iran Deal News -- Market Talk

29.05.2026 г., 15:55 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

29.05.2026 г., 15:55 ч. UTC

Пазарно говорене

Cryptocurrencies Appear Detached From Stocks -- Market Talk

29.05.2026 г., 15:50 ч. UTC

Придобивния, сливания и поглъщания

Johnson Matthey CEO: Cormetech Acquisition to Drive Growth

29.05.2026 г., 15:50 ч. UTC

Придобивния, сливания и поглъщания

Johnson Matthey CEO: Demand for AI Data Centers Insatiable

29.05.2026 г., 15:40 ч. UTC

Пазарно говорене

Kalshi To Launch Crypto Perpetual Futures -- Market Talk

29.05.2026 г., 15:20 ч. UTC

Пазарно говорене

Canada's Economy Not Looking All That Bright -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Syndax Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

106.74% нагоре

12-месечна прогноза

Среден 40.5 USD 106.74%

Висок 57 USD

Нисък 29 USD

Според 11 анализатори от Wall Street, предложили 12-месечна ценова цел за Syndax Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

11 ratings

Купи

Задържане

Продай

Според 11 анализатори, дали борсови рейтинги на Syndax Pharmaceuticals Inc през последните 3 месеца.

Настроение

By Acuity

161 / 344 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.